Gossamer Bio, INC Form 4 insider transactions

Gossamer Bio director John D. Quisel was granted 115,000 stock options as part of the company's non-employee director compensation program.

Director Skye Drynan was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Director Daniel Thomas O was granted 115,000 stock options in Gossamer Bio, Inc. as part of the company's non-employee director compensation program.

Director Russell J. Cox was granted 115,000 stock options as part of the Gossamer Bio, Inc. non-employee director compensation program.

Director Sandra Milligan was granted 115,000 stock options as part of the Gossamer Bio Non-Employee Director Compensation Program.

Director Steven D. Nathan was granted 115,000 stock options as part of the Gossamer Bio, Inc. non-employee director compensation program.

Gossamer Bio's Chief Medical Officer, Richard Aranda, had over 1.9 million stock options repriced to an exercise price of $0.45 per share, effective March 19, 2026.

Gossamer Bio, Inc. has repriced nearly 2 million outstanding stock options for EVP Caryn Peterson to an exercise price of $0.45 per share, effective March 19, 2026.

Gossamer Bio, Inc. has repriced Chief Commercial Officer Robert Paul Smith JR's stock options, significantly reducing their exercise price to $0.45 per share.

Gossamer Bio, Inc. has repriced President and CEO Faheem Hasnain's outstanding stock options to an exercise price of $0.45 per share, effective March 19, 2026.

Gossamer Bio's COO/CFO Bryan Giraudo had a significant portion of his outstanding stock options repriced to an exercise price of $0.45 per share.

Gossamer Bio, Inc. repriced certain outstanding stock options for EVP Christian Waage to an exercise price of $0.45 per share, effective March 19, 2026.

Gossamer Bio's President and CEO, Faheem Hasnain, received a substantial restricted stock unit award and stock options, signaling long-term incentive alignment.

Gossamer Bio's COO/CFO, Bryan Giraudo, received significant equity awards, including restricted stock units and stock options, under a pre-arranged plan.

Gossamer Bio's Chief Commercial Officer, Robert Paul Smith JR, was granted 93,750 restricted stock units and 562,500 stock options on January 2, 2026.

Gossamer Bio's Chief Medical Officer, Richard Aranda, was granted significant equity awards, including restricted stock units and stock options, effective January 2, 2026.

Gossamer Bio's EVP of Regulatory Affairs, Caryn Peterson, received substantial restricted stock units and stock options, aligning her interests with long-term company performance.

Gossamer Bio's EVP of Technical Operations and Administration, Christian Waage, received significant equity awards, including restricted stock units and stock options, effective January 2, 2026.

Gossamer Bio's Chief Commercial Officer, Robert Paul Smith Jr., was granted 162,500 performance stock units, contingent on key corporate milestones.

Gossamer Bio's EVP of Tech Ops and Admin, Christian Waage, was granted 125,000 performance stock units, vesting upon key milestones.

Gossamer Bio's COO/CFO, Bryan Giraudo, received 181,250 performance stock units tied to key drug development milestones.

Gossamer Bio's Chief Medical Officer, Richard Aranda, was granted 162,500 performance stock units, vesting upon key milestones related to seralutinib or a change in control.

Gossamer Bio's President and CEO, Faheem Hasnain, was granted 437,500 performance stock units, vesting upon key milestones related to seralutinib or a change in control.

Gossamer Bio's EVP of Regulatory Affairs, Caryn Peterson, received 125,000 performance stock units tied to seralutinib NDA approval or a change in control.

Gossamer Bio Director Sandra Milligan acquired 26,050 shares of common stock at $1.92 per share, increasing her direct holdings.

Gossamer Bio, Inc. Director Daniel Thomas O was granted 115,000 stock options with an exercise price of $1.36 as part of the company's Non-Employee Director Compensation Program.

Gossamer Bio, Inc. Director Nathan Steven D was granted 115,000 stock options at an exercise price of $1.36 as part of the company's Non-Employee Director Compensation Program.

Gossamer Bio, Inc. Director Russell J. Cox was granted 115,000 stock options with an exercise price of $1.36 as part of the company's Non-Employee Director Compensation Program.

Gossamer Bio, Inc. Director John D. Quisel was granted 115,000 stock options with an exercise price of $1.36 per share, as part of the company's Non-Employee Director Compensation Program.

Gossamer Bio, Inc. Director Sandra Milligan was granted 115,000 stock options with an exercise price of $1.36 as part of her compensation.